Development services company ICON has been selected by pharmaceuticals giant Pfizer as a global strategic partner for clinical research and development.
ICON will be one of two preferred providers of clinical trial implementation services.
The partnership will be implemented over 18-24 months.
'We look forward to working with Pfizer to help realise their development pipeline and expect that over time our partnership will have a significant positive impact on ICON's future growth,' said ICON chief executive Peter Gray.
